Search
P3 Health Partners Inc
PIIIAdd to Watchlist
10.005USD
-0.495-4.71%
Market hours （ET）Quotes delayed by 15 min
32.96MMarket Cap
0.04P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-29The current earnings forecast score of P3 Health Partners Inc is 7.00, ranking 313 out of 384 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 12.50 and a low of 8.00.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
14.000
Target Price
+33.59%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
P3 Health Partners Inc
PIII
2
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is P3 Health Partners Inc's expected revenue for the next quarter?
P3 Health Partners Inc's expected revenue is 377.95M.
What is P3 Health Partners Inc's price target?
Analysts forecast that P3 Health Partners Inc's price target is USD 11.00, with the highest forecast at USD 12.50 and the lowest forecast at USD 8.00.
How have P3 Health Partners IncPIII's recent earnings per share performed?
The market expectation was USD 0.37, while P3 Health Partners IncPIII's earnings per share (EPS) for the previous quarter was USD -23.02. EPS for the next quarter is expected at USD -1.90.
What is the analyst rating for P3 Health Partners Inc?
Based on the ratings of P3 Health Partners Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.